Emmaus Life Sciences, Inc.
EMMA
$0.0165
$0.001510.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -53.42% | 9.17% | -50.02% | -62.89% | 19.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.42% | 9.17% | -50.02% | -62.89% | 19.17% |
| Cost of Revenue | 61.78% | 84.11% | -52.56% | -40.09% | -70.39% |
| Gross Profit | -56.62% | 5.83% | -49.90% | -64.44% | 30.10% |
| SG&A Expenses | -36.45% | -5.70% | -33.94% | -33.25% | -13.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.62% | -6.75% | -35.49% | -33.75% | -22.26% |
| Operating Income | -141.11% | 3,320.83% | -82.50% | -135.19% | 195.56% |
| Income Before Tax | -258.80% | 1,639.05% | -35.24% | -28.01% | 407.87% |
| Income Tax Expenses | 105.36% | -102.63% | 191.18% | -114.29% | -800.00% |
| Earnings from Continuing Operations | -244.58% | 2,626.87% | -40.18% | -25.99% | 504.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -244.58% | 2,626.87% | -40.18% | -25.99% | 504.50% |
| EBIT | -141.11% | 3,320.83% | -82.50% | -135.19% | 195.56% |
| EBITDA | -140.56% | 2,481.25% | -82.37% | -136.51% | 196.87% |
| EPS Basic | -225.11% | 2,283.33% | -16.95% | -3.23% | 447.50% |
| Normalized Basic EPS | -218.06% | 103.41% | -3.92% | -29.83% | 289.19% |
| EPS Diluted | -279.78% | 2,140.00% | -16.95% | -3.23% | 345.00% |
| Normalized Diluted EPS | -218.06% | 105.88% | -3.92% | -29.83% | 289.19% |
| Average Basic Shares Outstanding | 15.74% | 19.07% | 19.84% | 21.96% | 11.32% |
| Average Diluted Shares Outstanding | 15.74% | 17.60% | 19.84% | 21.96% | 11.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |